DICE Therapeutics Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Employee Data

  • DICE Therapeutics has 91 Employees.(i)
  • DICE Therapeutics grew their employee count by 127% last year.

DICE Therapeutics's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Executive Assistant to CEO & CFOReveal Email/Phone
3
Chief Business & Financial OfficerReveal Email/Phone
4
Chief Scientific OfficerReveal Email/Phone
5
VP, Clinical DevelopmentReveal Email/Phone
6
VP RegulatoryReveal Email/Phone
7
VP, FinanceReveal Email/Phone
8
VP, Medicinal Chemistry Reveal Email/Phone
9
VP, Process Chemistry, DICE TherapeuticsReveal Email/Phone
10
VP Information TechnologyReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is DICE Therapeutics?

At DICE, we are expecting more out of medicine. We design and develop innovative oral medicines against biologically validated targets in immunology for the treatment of chronic autoimmune and inflammatory diseases. Through combining innovative chemistry with well-validated biology, our goal is to make medicines more accessible and unlock the potential of oral medicines.\n\nOur team is led by an exceptional group of scientists, R&D executives and company builders with demonstrated track records of progressing programs from discovery through regulatory approval and commercialization. Together, we’re building a team that has a passion for innovation and extensive experience in small molecule drug discovery and development.

keywords:N/A

N/A

Total Funding

91

Number of Employees

N/A

Revenue (est)

127%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$14.3M92-25%$253M
#2
$16.6M956%N/A
#3
$4M99-7%$308.6M
#4
$21M1004%N/A
#5
$27.5M1021%N/A